Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are ambulatory.~* Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.~* Participants have a history of back pain ≥3 months with age at onset \<45 years.~* Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.~* Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.~* Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.~Exclusion Criteria:~* Have total ankylosis of the spine.~* Have never taken a TNF inhibitor medication or have taken more than 2.~* Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.~* Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.~* Have a compromised immune system.~* Have any other serious and/or uncontrolled diseases.~* Have either a current diagnosis or a recent history of malignant disease.~* Have had major surgery within 8 weeks of baseline, or will require surgery during the study.~* Are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
- Q4W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).